Tatva Chintan Pharma Chem Limited, a specialty chemicals manufacturing company engaged in the manufacturing of diverse portfolio of structure directing agents, phase transfer catalysts, electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals, is proposing to open its initial public offering (IPO) of equity shares on July 16, 2021.

The price band of the offer has been fixed at Rs. 1,073 - 1,083 per equity share. Bids can be made for a minimum of 13 equity shares and in multiples of 13 equity shares thereafter.

The offer comprises of a fresh issue of such number of equity shares aggregating up to Rs. 225 crore and an offer for sale of up to aggregating up to Rs. 275 crore, with a sale of such number of equity shares aggregating up to Rs. 23.3 crore by Ajaykumar Mansukhlal Patel, such number of equity shares aggregating up to Rs. 81.4 crore by Chintan Nitinkumar Shah, and up to Rs. 73 crore by Shekhar Rasiklal Somani, and up to Rs. 10.3 crore by Darshana Nitinkumar Shah, up to Rs. 34.2 crore by Priti Ajaykumar Patel, up to Rs. 34.2 crore by Ajay Mansukhlal Patel HUF, up to Rs. 11 crore by Kajal Shekhar Somani, up to Rs. 1.1 core by Shitalkumar Rasiklal Somani, and up to Rs. 6.5 crore by Samirkumar Rasiklal Somani.

This offer is being made through the Book Building Process in accordance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (QIBs), provided that the company in consultation with the BRLMs may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis.

One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price. 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB bidders, including Mutual Funds, subject to valid bids being received at or above the offer price.

Further, not less than 15% of the offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the offer shall be available for allocation to Retail Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid bids being received from them at or above the offer price.